How OMass Therapeutics is tackling congenital adrenal hyperplasia, a uncommon genetic dysfunction

Ros Deegan is an business chief and the CEO of OMass Therapeutics, an Oxford-based biotechnology firm discovering medicines towards highly-validated goal ecosystems, resembling membrane proteins or intracellular complexes.  

OMass’s MC2 program focusing on Congenital Adrenal Hyperplasia, or CAH, is ready to enter the clinic this 12 months and in our interview at present she walks me via how the corporate is getting ready for his or her trials, how their strategy differs to present remedy choices, and the impression on affected person lives they hope to have. A frontrunner within the UK biopharma business, she additionally explains the strengths of the UK business and the way it can keep an edge within the face of competitors from Europe and the US.

01:07   Meet Ros Deegan

02:36   Cambridge and INSEAD

04:24   Constructing business expertise

05:16   Biotech within the US vs Biotech within the UK

06:19   OMass: mission and ambition

07:16   Funding the mission

08:18   The significance of partnerships

09:17   Business and authorities

10:37   OMass and CAH

13:11   The differentiator for affected person outcomes

14:49   Into the clinic in 2025

16:31   CAH sufferers and affected person teams

19:29   The significance of hiring the correct individuals

20:55   The Oxford ‘model’ in biotechnology

22:17   Making ready for the clinic

23:43   Regulation and manufacturing

26:17   Partnering with high pharma

27:35   The significance of constructing worth

28:41   How the UK can compete on a world scale

30:39   What’s subsequent for OMass

32:59   The way forward for focusing on uncommon illness

Enthusiastic about being a sponsor of an episode of our podcast? Uncover how one can become involved right here! 

Keep up to date by subscribing to our publication

To dive deeper into the subject: